Truist Securities Reiterates Buy on Eli Lilly, Maintains $650 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Eli Lilly (NYSE:LLY) and maintained a price target of $650.

November 29, 2023 | 6:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities reaffirms a Buy rating on Eli Lilly with a price target of $650, indicating a positive outlook on the stock.
Analyst ratings, especially from reputable firms like Truist Securities, can influence investor sentiment and stock prices. The reiteration of a Buy rating and a high price target suggests a strong conviction in the company's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100